This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

Schizophrenia International Research Society
May 11th – 15th 2023, Toronto, ON
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Bipolar Disorder
Schizophrenia
POSTER
Preferences for Characteristics of Oral Antipsychotic Treatments: Survey Results of Patients Living With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Michael J. Doane,1 Marco Boeri,2,3 Caroline Vass,4,5 Cooper Bussberg,6 Hemangi R. Panchmatia,1 Sabina Gasper,1 Leslie Citrome,7 Martha Sajatovic8

Schizophrenia
ENCORE POSTER
Use of Long-Acting Antipsychotic Treatments in Community Telepsychiatry Study to Assess Knowledge, Attitudes, and Perceived Barriers From Patients’, Caregivers’, and Providers’ Perspective in South Carolina (LATITUDE Study)
AUTHOR(S)

Meera Narasimhan,1 Suzanne Hardeman,1 Casey Childers,1 Amanda Edgar,1 Amy Claxton,2* Elizabeth Keane,2 Batool A. Haider,2 Brittany D. Roy,2* Cory Saucier,3 Sergey Yagoda2